CELLECTIS - ADR (CLLS) Stock Price & Overview
NASDAQ:CLLS • US15117K1034
Current stock price
The current stock price of CLLS is 3.38 USD. Today CLLS is up by 6.62%. In the past month the price decreased by -9.87%. In the past year, price increased by 193.91%.
CLLS Key Statistics
- Market Cap
- 339.998M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.67
- Dividend Yield
- N/A
CLLS Stock Performance
CLLS Stock Chart
CLLS Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to CLLS. When comparing the yearly performance of all stocks, CLLS is one of the better performing stocks in the market, outperforming 94.37% of all stocks.
CLLS Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to CLLS. CLLS may be in some trouble as it scores bad on both profitability and health.
CLLS Earnings
On March 19, 2026 CLLS reported an EPS of -0.26 and a revenue of 12.21M. The company beat EPS expectations (1.78% surprise) and missed revenue expectations (-4.74% surprise).
CLLS Forecast & Estimates
13 analysts have analysed CLLS and the average price target is 7.62 USD. This implies a price increase of 125.48% is expected in the next year compared to the current price of 3.38.
For the next year, analysts expect an EPS growth of -76.28% and a revenue growth -7.73% for CLLS
CLLS Groups
Sector & Classification
CLLS Financial Highlights
Over the last trailing twelve months CLLS reported a non-GAAP Earnings per Share(EPS) of -0.67. The EPS decreased by -91.43% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -26.22% | ||
| ROE | -112.16% | ||
| Debt/Equity | 1.34 |
CLLS Ownership
CLLS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.49 | 380.121B | ||
| AMGN | AMGEN INC | 15.48 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.87 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.07 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.62 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.06 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.43 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.09 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.31 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About CLLS
Company Profile
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
Company Info
IPO: 2007-02-06
CELLECTIS - ADR
8, rue de la Croix Jarry
Paris ILE-DE-FRANCE 75013 FR
CEO: Andre Choulika
Employees: 219
Phone: 33181691600
CELLECTIS - ADR / CLLS FAQ
What does CELLECTIS - ADR do?
Cellectis SA operates as a clinical stage biotechnological company, which engages in gene-editing platform to develop cell and gene therapies. The company is headquartered in Paris, Ile-De-France and currently employs 224 full-time employees. The company went IPO on 2007-02-06. The firm specializes in the research, development, and commercialization of rational genome engineering technologies. The firm develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. The company has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The firm operates in France and the United States, among others.
What is the stock price of CELLECTIS - ADR today?
The current stock price of CLLS is 3.38 USD. The price increased by 6.62% in the last trading session.
What is the dividend status of CELLECTIS - ADR?
CLLS does not pay a dividend.
What is the ChartMill rating of CELLECTIS - ADR stock?
CLLS has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the Price/Earnings (PE) ratio of CELLECTIS - ADR (CLLS)?
CELLECTIS - ADR (CLLS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.67).
Should I buy CLLS stock?
This depends on your investment goals. Check the Technical and Fundamental Analysis tabs for insights on CLLS.
Can you provide the market cap for CELLECTIS - ADR?
CELLECTIS - ADR (CLLS) has a market capitalization of 340.00M USD. This makes CLLS a Small Cap stock.